These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 37839733)
41. Topical minoxidil: review of efficacy and safety. Katz HI Cutis; 1989 Jan; 43(1):94-8. PubMed ID: 2644080 [TBL] [Abstract][Full Text] [Related]
42. The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia. Faghihi G; Mozafarpoor S; Asilian A; Mokhtari F; Esfahani AA; Bafandeh B; Nouraei S; Nilforoushzadeh MA; Hosseini SM Indian J Dermatol Venereol Leprol; 2018; 84(5):547-553. PubMed ID: 30027912 [TBL] [Abstract][Full Text] [Related]
43. The use of minoxidil in the treatment of male and female androgenetic alopecia: a story of more than 30 years. Barbareschi M G Ital Dermatol Venereol; 2018 Feb; 153(1):102-106. PubMed ID: 29319278 [TBL] [Abstract][Full Text] [Related]
44. Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia. Sanabria BD; Palmegiani E; Seron AF; Perdomo YC; Miot HA; Müller Ramos P J Am Acad Dermatol; 2023 Feb; 88(2):436-437. PubMed ID: 35597386 [No Abstract] [Full Text] [Related]
45. Response to Desai et al, "Response to 'Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study'". Ong M; Lipner SR J Am Acad Dermatol; 2024 Jul; 91(1):e9-e10. PubMed ID: 38499180 [No Abstract] [Full Text] [Related]
46. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. Suchonwanit P; Rojhirunsakool S; Khunkhet S Lasers Med Sci; 2019 Dec; 34(9):1857-1864. PubMed ID: 30982177 [TBL] [Abstract][Full Text] [Related]
47. SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth. Dhurat R; Daruwalla S; Pai S; Kovacevic M; McCoy J; Shapiro J; Sinclair R; Vano-Galvan S; Goren A J Cosmet Dermatol; 2022 Jan; 21(1):343-346. PubMed ID: 34133836 [TBL] [Abstract][Full Text] [Related]
48. Topical 5% minoxidil versus combined erbium YAG laser and topical 5% minoxidil in androgenetic alopecia: A randomized controlled trial. Mokhtari F; Zavare Z; Iraji F J Cosmet Dermatol; 2023 Oct; 22(10):2737-2743. PubMed ID: 37574862 [TBL] [Abstract][Full Text] [Related]
50. Efficacy of autologous platelet-rich plasma therapy versus topical Minoxidil in men with moderate androgenetic alopecia: a randomized open-label trial. Balasundaram M; Kumari R; Ramassamy S J Dermatolog Treat; 2023 Dec; 34(1):2182618. PubMed ID: 36800229 [TBL] [Abstract][Full Text] [Related]
51. Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice? Mapar MA; Omidian M J Dermatolog Treat; 2007; 18(5):268-70. PubMed ID: 17917938 [TBL] [Abstract][Full Text] [Related]
52. Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. Goren A; Sharma A; Dhurat R; Shapiro J; Sinclair R; Situm M; Kovacevic M; Lukinovic Skudar V; Goldust M; Lotti T; McCoy J Dermatol Ther; 2018 Nov; 31(6):e12741. PubMed ID: 30226287 [TBL] [Abstract][Full Text] [Related]
53. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Blume-Peytavi U; Hillmann K; Dietz E; Canfield D; Garcia Bartels N J Am Acad Dermatol; 2011 Dec; 65(6):1126-1134.e2. PubMed ID: 21700360 [TBL] [Abstract][Full Text] [Related]
54. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Sharma A; Goren A; Dhurat R; Agrawal S; Sinclair R; Trüeb RM; Vañó-Galván S; Chen G; Tan Y; Kovacevic M; Situm M; McCoy J Dermatol Ther; 2019 May; 32(3):e12915. PubMed ID: 30974011 [TBL] [Abstract][Full Text] [Related]
56. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Goren A; Castano JA; McCoy J; Bermudez F; Lotti T Dermatol Ther; 2014; 27(3):171-3. PubMed ID: 24283387 [TBL] [Abstract][Full Text] [Related]
57. Topical minoxidil therapy for androgenetic alopecia. A 30-month study. Koperski JA; Orenberg EK; Wilkinson DI Arch Dermatol; 1987 Nov; 123(11):1483-7. PubMed ID: 3314717 [TBL] [Abstract][Full Text] [Related]
58. An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia. Dhurat R; Chitallia J; May TW; Jayaraaman AM; Madhukara J; Anandan S; Vaidya P; Klenk A Skin Pharmacol Physiol; 2017; 30(6):298-305. PubMed ID: 29055953 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. Ghonemy S; Alarawi A; Bessar H J Dermatolog Treat; 2021 Mar; 32(2):236-241. PubMed ID: 31403367 [TBL] [Abstract][Full Text] [Related]
60. Placebo-controlled dose-effect studies with topical minoxidil 2% or 5% in male-patterned hair loss treated with oral finasteride employing an analytical and exhaustive study protocol. Van Neste D Skin Res Technol; 2020 Jul; 26(4):542-557. PubMed ID: 31957152 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]